Ad
related to: how to give neulasta injection- Amneal PATHways®
Get resources & services to support
accessibility for patients
- Biosciences Products
Learn more about our
biosimilar injectables
- Biosimilar FAQs
See FAQs to help you
understand biosimilars
- Useful Resources
Download any of our
helpful resources
- Amneal PATHways®
Search results
Results from the WOW.Com Content Network
Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. [19] It serves to stimulate the production of white blood cells ( neutrophils ).
Filgrastim (Neupogen) and PEG-filgrastim (Neulasta), or pegylated form of filgratim, are two commercially available forms of rhG-CSF. The pegylated form of filgratim form has a much longer half-life, reducing the necessity of daily injections. The FDA approved the first biosimilar of Neulasta in June 2018.
It is given either by injection into a vein or under the skin. [21] Filgrastim is a leukocyte growth factor. [20] Common side effects include fever, cough, chest pain, joint pain, vomiting, and hair loss. [21] Severe side effects include splenic rupture and allergic reactions. [21] It is unclear if use in pregnancy is safe for the baby. [21]
Ziextenzo is a biosimilar product to Amgen's (AMGN) Neulasta and the name under which the company trades pegfilgrastim. Pegfilgrastim, a white blood cell production stimulator, represents a remedy ...
For premium support please call: 800-290-4726 more ways to reach us
Intrathecal administration is a route of administration for drugs via an injection into the spinal canal, or into the subarachnoid space so that it reaches the cerebrospinal fluid (CSF). It is useful in several applications, such as for spinal anesthesia, chemotherapy, or pain management. This route is also used to introduce drugs that fight ...
The FDA announced on Tuesday that it has issued an emergency use authorization to allow healthcare providers to give the vaccine via an intradermal injection vs. the previous subcutaneous ...
Efbemalenograstim alfa can cause fatal splenic rupture, acute respiratory distress syndrome, serious allergic reactions including anaphylaxis, sickle cell crises in patients with sickle cell disorders, glomerulonephritis, thrombocytopenia, capillary leak syndrome, and myelodysplastic syndrome and acute myeloid leukemia in people with breast and lung cancer.
Ad
related to: how to give neulasta injection